S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
S&P 500   2,789.82 (+1.45%)
DOW   23,719.37 (+1.22%)
QQQ   200.86 (+0.14%)
AAPL   267.99 (+0.72%)
FB   175.19 (+0.52%)
MSFT   165.14 (+0.01%)
GOOGL   1,206.57 (-0.04%)
AMZN   2,042.76 (-0.01%)
CGC   14.57 (-1.75%)
NVDA   262.86 (-1.53%)
BABA   196.37 (+0.20%)
MU   46.13 (-4.47%)
GE   7.14 (-2.19%)
TSLA   573.00 (+4.40%)
AMD   48.38 (-0.84%)
T   30.73 (+2.81%)
ACB   0.88 (+2.34%)
F   5.37 (+6.76%)
NFLX   370.81 (-0.08%)
BAC   24.86 (+6.01%)
GILD   73.51 (-1.97%)
DIS   104.50 (+3.39%)
PRI   102.14 (+4.75%)
Log in

LON:PEBIPort Erin Biopharma Investments Share Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume7,434 shs
Market Capitalization£1.04 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Port Erin Biopharma Investments Limited is a principal investment firm specializing in investments in equity and equity related products. The firm invests in quoted and unquoted companies. It prefers to invest in the biopharma sector and will establish a portfolio of investments in biotechnology and biopharmaceutical companies. The firm may also invest in shares of collective investment schemes with exposure to the biopharma sector and in long-term equity anticipation securities the underlying securities of which will be based on biopharma sector securities and/or indices relating to the biopharma Sector. It may invest in biopharma sector debt, where investments shall not exceed 15 per cent of the net asset value of the company. Port Erin Biopharma Investments Limited was founded on May 3, 2011 and is based in Isle of Man, United Kingdom.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1624-620711

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£28,300.00
Book ValueGBX 8.10 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap£1.04 million
Next Earnings DateN/A
OptionableNot Optionable

Receive PEBI News and Ratings via Email

Sign-up to receive the latest news and ratings for PEBI and its competitors with MarketBeat's FREE daily newsletter.


Port Erin Biopharma Investments (LON:PEBI) Frequently Asked Questions

Has Port Erin Biopharma Investments been receiving favorable news coverage?

Press coverage about PEBI stock has trended very negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Port Erin Biopharma Investments earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutPort Erin Biopharma Investments.

Who are some of Port Erin Biopharma Investments' key competitors?

Who are Port Erin Biopharma Investments' key executives?

Port Erin Biopharma Investments' management team includes the following people:
  • Mr. Denham Hervey Newall Eke, CFO, Fin. Director & Director (Age 67)

What is Port Erin Biopharma Investments' stock symbol?

Port Erin Biopharma Investments trades on the London Stock Exchange (LON) under the ticker symbol "PEBI."

How do I buy shares of Port Erin Biopharma Investments?

Shares of PEBI and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How big of a company is Port Erin Biopharma Investments?

Port Erin Biopharma Investments has a market capitalization of £0.00 and generates £28,300.00 in revenue each year.  View additional information about Port Erin Biopharma Investments.

What is Port Erin Biopharma Investments' official website?

The official website for Port Erin Biopharma Investments is http://www.porterinbiopharma.com/.

How can I contact Port Erin Biopharma Investments?

Port Erin Biopharma Investments' mailing address is 18 Athol Street, DOUGLAS, IM1 1JA, Isle of Man. The company can be reached via phone at +44-1624-620711.

This page was last updated on 4/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel